AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11330365 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 6 days
Number of subjects: 151
Study 11330365 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 14 days
Number of subjects: 151
Study 11330365 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 1.0 g single dose
Number of subjects: 151
Study 11330365 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg b.i.d. for 7 days
Number of subjects: 151
Study 8989017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms/kg
Number of subjects: 14
Study 8989017 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate 8 micrograms/kg
Number of subjects: 14
Study 8432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 12
Study 8432669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OMT)
Number of subjects: 12
Study 3322472 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide disinfection of drainage bags
Number of subjects: 0
Study 3322472 — intervention group
Group type: COMPARATOR
Intervention: No disinfection technique (Control)
Number of subjects: 0
Study 30941550 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic group (LG)
Number of subjects: 193
Study 30941550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid group (HG)
Number of subjects: 193
Study 30941550 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 193
Study 30579334 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air skin surface warming for 20 minutes before spinal anesthesia (pre-warming group, n=25)
Number of subjects: 50
Study 30579334 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation (control group, n=25)
Number of subjects: 50
Study 27492064 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic regimen
Number of subjects: 77
Study 27492064 — intervention group
Group type: COMPARATOR
Intervention: 5-day antibiotic regimen
Number of subjects: 77
Study 27492064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 77
Study 26280590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 80
Study 26280590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24345687 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 20
Study 24345687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission of body weight (BW)
Number of subjects: 20
Study 20887606 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership in Coping during a 3‐month clinical intervention period
Number of subjects: 56
Study 20887606 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (Control)
Number of subjects: 56
Study 18773729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion
Number of subjects: 0
Study 18773729 — intervention group
Group type: EXPERIMENTAL
Intervention: Negation
Number of subjects: 0
Study 18773729 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent manipulation of hue and luminance
Number of subjects: 0
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: iv arginine (ARG, 0.5 g/kg)
Number of subjects: 6
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: oral protein load (PRO, 50 g)
Number of subjects: 6
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: iv lipid‐heparin infusion (Li He, Intralipid 10% 250 ml)
Number of subjects: 6
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: oral fat load (OIL, soy oil 40 g)
Number of subjects: 6
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: oral glucose load (OGL, 100 g)
Number of subjects: 6
Study 17061019 — intervention group
Group type: EXPERIMENTAL
Intervention: oral fructose load (OFL, 100 g)
Number of subjects: 6
Study 17061019 — intervention group
Group type: COMPARATOR
Intervention: iv saline (SAL, 3 ml)
Number of subjects: 6
Study 17061019 — intervention group
Group type: COMPARATOR
Intervention: oral water load (WL, 200 ml)
Number of subjects: 6
Study 12925043 — intervention group
Group type: COMPARATOR
Intervention: 50-mg day-1 dose of naltrexone
Number of subjects: 204
Study 12925043 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg day-1 dose of methadone
Number of subjects: 204
Study 12925043 — intervention group
Group type: COMPARATOR
Intervention: 5-mg day-1 dose of buprenorphine
Number of subjects: 204
Study 11029729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lingual arch treatment
Number of subjects: 23
Study 11029729 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched individuals)
Number of subjects: 23
Study 9060545 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus placebo
Number of subjects: 20
Study 9060545 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus rhuTNFR:Fc
Number of subjects: 20
Study 8370294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micrograms/kg/min)
Number of subjects: 16
Study 8370294 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (800 mL of packed red blood cells in 90 mins)
Number of subjects: 16
Study 3720755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention programme including antihypertensive treatment, dietary advice, and smoking cessation advice applied for 10 years.
Number of subjects: 10004
Study 3720755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 10004
Study 30115110 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care
Number of subjects: 0
Study 30115110 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27671517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR) + photodynamic therapy (PDT) with alasens
Number of subjects: 45
Study 23591944 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 47
Study 23591944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 47
Study 23591944 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (No Stretching)
Number of subjects: 47
Study 22224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) and standard care
Number of subjects: 60
Study 22224756 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 60
Study 20165833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol graft
Number of subjects: 61
Study 20165833 — intervention group
Group type: COMPARATOR
Intervention: Conventional anterior repair
Number of subjects: 61
Study 18755762 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care (minimum of one hour of care by a nurse or midwife trained in structured care)
Number of subjects: 5002
Study 18755762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (usual nursing or midwifery care)
Number of subjects: 5002
Study 18755762 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care
Number of subjects: 5002
Study 15966083 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end (ETE) distal anastomosis
Number of subjects: 274
Study 15966083 — intervention group
Group type: COMPARATOR
Intervention: End-to-side (ETS) distal anastomosis
Number of subjects: 274
Study 12762176 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (single intravenous dose)
Number of subjects: 24
Study 12762176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study 9789586 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + drug
Number of subjects: 42
Study 9789586 — intervention group
Group type: COMPARATOR
Intervention: Drug
Number of subjects: 42
Study 9789586 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAO + EA
Number of subjects: 42
Study 9789586 — intervention group
Group type: COMPARATOR
Intervention: MCAO
Number of subjects: 42
Study 8998394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (n = 31)
Number of subjects: 81
Study 8998394 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (n = 11)
Number of subjects: 81
Study 3230148 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fructose‐1,6‐diphosphate (FDP)
Number of subjects: 10
Study 3230148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 10
Study 29663958 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messaging for TB-related communications
Number of subjects: 348
Study 29663958 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice calls for TB-related communications
Number of subjects: 348
Study 29131079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during myocardial infarction (MI)
Number of subjects: 140
Study 26333890 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acid supplementation (four 1000-mg supplements daily containing eicosapentaenoic acid 1200 mg plus docosahexaenoic acid 800 mg)
Number of subjects: 51
Study 26333890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four 1000-mg paraffin oil placebo capsules daily)
Number of subjects: 51
Study 23296436 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROfile discussed during consultation
Number of subjects: 176
Study 23296436 — intervention group
Group type: COMPARATOR
Intervention: Control period (ePROfile not discussed)
Number of subjects: 176
Study 20868642 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 338
Study 20868642 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 338
Study 20868642 — intervention group
Group type: COMPARATOR
Intervention: Both dosages
Number of subjects: 338
Study 19186973 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-G gel (ascorbic acid 2-glucoside) applied for 12 weeks
Number of subjects: 73
Study 19186973 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied for 12 weeks
Number of subjects: 73
Study 17991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) as the primary endpoint in symptom management trials
Number of subjects: 0
Study 17991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis and interpretation of PROs
Number of subjects: 0
Study 17991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodologic aspects of design, analysis, and interpretation of symptom management trials
Number of subjects: 0
Study 15557828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone
Number of subjects: 40
Study 15557828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11746299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 94
Study 11746299 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (WL) control group
Number of subjects: 94
Study 9644707 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration sets changed every 48 hours
Number of subjects: 50
Study 9644707 — intervention group
Group type: COMPARATOR
Intervention: i.v. administration sets changed every 24 hours
Number of subjects: 50
Study 7936368 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline enriched water (400 ml at 33 degrees C)
Number of subjects: 24
Study 7936368 — intervention group
Group type: COMPARATOR
Intervention: Oligomineral water (400 ml at 33 degrees C)
Number of subjects: 24
Study 7936368 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline enriched water (400 ml at 18 degrees C)
Number of subjects: 24
Study 7936368 — intervention group
Group type: COMPARATOR
Intervention: Oligomineral water (400 ml at 18 degrees C)
Number of subjects: 24
Study 3914998 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cc of 1% lidocaine
Number of subjects: 41
Study 3914998 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 31696836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily + LiESWT (2400 shockwaves)
Number of subjects: 78
Study 31696836 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg once daily alone
Number of subjects: 78
Study 30078935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 0
Study 30078935 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 0
Study 27759486 — intervention group
Group type: EXPERIMENTAL
Intervention: Compaction technique
Number of subjects: 20
Study 27759486 — intervention group
Group type: COMPARATOR
Intervention: Broaching technique
Number of subjects: 20
Study 27759486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - rosiglitazone
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - pioglitazone
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - overall
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - cumulative duration
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - lumbar spine BMD
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - femoral neck BMD
Number of subjects: 24544
Study 25173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - hip BMD
Number of subjects: 24544
Study 22994170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Forever Free for Baby and Me (FFB) relapse prevention booklets
Number of subjects: 504
Study 22994170 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (UCC) - 2 existing smoking cessation materials
Number of subjects: 504
Study 20837847 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (20 mg) plus albuterol (oral dose daily for 2 years)
Number of subjects: 44
Study 20837847 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (20 mg) plus placebo (oral dose daily for 2 years)
Number of subjects: 44
Study 18853554 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite face task administered at seven orientations
Number of subjects: 0
Study 17379119 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg . kg(‐1) IV
Number of subjects: 32
Study 17379119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralipid, one mL . kg(‐1))
Number of subjects: 32
Study 15078749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1070
Study 15078749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070
Study 10792152 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam (40 mg intravenously)
Number of subjects: 50
Study 10792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg intravenously) plus sublingual isosorbide dinitrate (5 mg)
Number of subjects: 50
Study 9286943 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) therapy
Number of subjects: 1932
Study 9286943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1932
Study 8472522 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-679 (1200 mg)
Number of subjects: 40
Study 8472522 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1000 mg)
Number of subjects: 40
Study 2871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyene fatty acid therapy (linseed oil, fish, and fish oil)
Number of subjects: 0
Study 2871668 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiatherogenic oil diet
Number of subjects: 0
Study 31132422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) supplementation (125 mg daily for 8 weeks)
Number of subjects: 60
Study 31132422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 mg of starch daily for 8 weeks)
Number of subjects: 60
Study 27477786 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride (SnF2) dentifrice (0.454% SnF2 + 0.077% sodium fluoride; total F = 1450 ppm F)
Number of subjects: 0
Study 27477786 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP)/arginine dentifrice (1.1% SMFP + 1.5% arginine; total F = 1450 ppm F)
Number of subjects: 0
Study 25568079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal lipid (long‐chain triglyceride emulsion)
Number of subjects: 13
Study 25568079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein (whey hydrolysate)
Number of subjects: 13
Study 25568079 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 13
Study 22918546 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast crawl
Number of subjects: 0
Study 22918546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast crawl)
Number of subjects: 0
Study 20728384 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine:naltrexone ratio 166:1
Number of subjects: 10
Study 20728384 — intervention group
Group type: COMPARATOR
Intervention: buprenorphine only
Number of subjects: 10
Study 19516117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) injection 1 week before surgery
Number of subjects: 41
Study 19516117 — intervention group
Group type: COMPARATOR
Intervention: No bevacizumab injection (Control)
Number of subjects: 41
Study 16984497 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole, 20 mg b.d.
Number of subjects: 13
Study 16984497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15558528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (25 to 200 mg once daily)
Number of subjects: 23
Study 15558528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11139906 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BV) pacing
Number of subjects: 222
Study 11139906 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 222
Study 9381772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (5 intraarticular injections, one injection per week for 5 weeks)
Number of subjects: 18
Study 9381772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 18
Study 8359970 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dietary history interview
Number of subjects: 1937
Study 8359970 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dietary history interview
Number of subjects: 1937
Study 8359970 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dietary history interview in heavier drinkers (> or = 20 g alcohol per day)
Number of subjects: 1937
Study 8359970 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate nutrients
Number of subjects: 1937
Study 2877681 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg kg‐1
Number of subjects: 59
Study 2877681 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.8 mg kg‐1
Number of subjects: 59
Study 2877681 — intervention group
Group type: COMPARATOR
Intervention: Control (no antagonist)
Number of subjects: 59
Study 30916447 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Bedside Entertainment and Relaxation Theater (BERT)
Number of subjects: 52
Study 30916447 — intervention group
Group type: COMPARATOR
Intervention: Tablet screen
Number of subjects: 52
Study 28799458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based physical activity program (12 weeks, daily 30-minute walks, individualized daily step targets)
Number of subjects: 37
Study 28799458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 37
Study 26679695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g nitrate (NIT)
Number of subjects: 20
Study 26679695 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo (PLA)
Number of subjects: 20
Study 24674307 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance testing and patient complaints
Number of subjects: 110
Study 24674307 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive events
Number of subjects: 110
Study 24674307 — intervention group
Group type: EXPERIMENTAL
Intervention: True cancer recurrences
Number of subjects: 110
Study 24674307 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing and healthcare consultations
Number of subjects: 110
Study 21325335 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse pull headgear (RPHG)
Number of subjects: 22
Study 21325335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 21325335 — intervention group
Group type: EXPERIMENTAL
Intervention: RPHG
Number of subjects: 22
Study 20955582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assisted discharge intervention (discharged on the fourth day of admission and treated at home)
Number of subjects: 0
Study 20955582 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient hospital care
Number of subjects: 0
Study 20955582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assisted discharge intervention
Number of subjects: 0
Study 19017042 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% niacinamide cosmetic applied for 8 weeks
Number of subjects: 30
Study 19017042 — intervention group
Group type: COMPARATOR
Intervention: Control cosmetic without niacinamide
Number of subjects: 30
Study 16082640 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 149
Study 16082640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12501045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg intravenously every 6 hours starting in the recovery room
Number of subjects: 112
Study 12501045 — intervention group
Group type: COMPARATOR
Intervention: Saline solution administered every 6 hours starting in the recovery room
Number of subjects: 112
Study 9578010 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/day TGB
Number of subjects: 123
Study 9578010 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg/day TGB
Number of subjects: 123
Study 9578010 — intervention group
Group type: EXPERIMENTAL
Intervention: TGB monotherapy
Number of subjects: 123